-
1
-
-
0034753972
-
Pituitary production of prolactin and prolactin-suppressing drugs
-
Tansey MJ, Schlecte JA. Pituitary production of prolactin and prolactin-suppressing drugs. Lupus 2001;10:660-664.
-
(2001)
Lupus
, vol.10
, pp. 660-664
-
-
Tansey, M.J.1
Schlecte, J.A.2
-
3
-
-
0031030299
-
Prolactin and prolactin receptors are expressed and functioning in human prostate
-
Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 1997;99:618-627.
-
(1997)
J Clin Invest
, vol.99
, pp. 618-627
-
-
Nevalainen, M.T.1
Valve, E.M.2
Ingleton, P.M.3
Nurmi, M.4
Martikainen, P.M.5
Harkonen, P.L.6
-
4
-
-
0035881316
-
A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice
-
Xu X, Kreye E, Kuo CB, Walker AM. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice. Cancer Res 2001;61:6098-6104.
-
(2001)
Cancer Res
, vol.61
, pp. 6098-6104
-
-
Xu, X.1
Kreye, E.2
Kuo, C.B.3
Walker, A.M.4
-
5
-
-
22944456517
-
Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer
-
Lissoni P, Bignami A, Frontini L, Manganini V, Dapretto E, Gardani GS, Vigano P, Strada G. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer. Int J Biol Markers 2005;20:123-125.
-
(2005)
Int J Biol Markers
, vol.20
, pp. 123-125
-
-
Lissoni, P.1
Bignami, A.2
Frontini, L.3
Manganini, V.4
Dapretto, E.5
Gardani, G.S.6
Vigano, P.7
Strada, G.8
-
6
-
-
0032993838
-
Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions
-
Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE, Ho SM. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol 1999;154:863-870.
-
(1999)
Am J Pathol
, vol.154
, pp. 863-870
-
-
Leav, I.1
Merk, F.B.2
Lee, K.F.3
Loda, M.4
Mandoki, M.5
McNeal, J.E.6
Ho, S.M.7
-
7
-
-
0030886337
-
Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland
-
Wennbo H, Kindblom J, Isaksson OGP, Tornell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997;138:4410-4415.
-
(1997)
Endocrinology
, vol.138
, pp. 4410-4415
-
-
Wennbo, H.1
Kindblom, J.2
Isaksson, O.G.P.3
Tornell, J.4
-
8
-
-
0242721070
-
Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate
-
Dillner K, Kindblom J, Flores-Morales A, Shao R, Tornell J, Norstedt G, Wennbo H. Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. Endocrinology 2003;144:4955-4966.
-
(2003)
Endocrinology
, vol.144
, pp. 4955-4966
-
-
Dillner, K.1
Kindblom, J.2
Flores-Morales, A.3
Shao, R.4
Tornell, J.5
Norstedt, G.6
Wennbo, H.7
-
9
-
-
0038662735
-
Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin
-
Kindblom J, Dillner K, Sahlin L, Robertson F, Ormandy C, Tornell J, Wennbo H. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 2003;144:2269-2278.
-
(2003)
Endocrinology
, vol.144
, pp. 2269-2278
-
-
Kindblom, J.1
Dillner, K.2
Sahlin, L.3
Robertson, F.4
Ormandy, C.5
Tornell, J.6
Wennbo, H.7
-
10
-
-
0031730446
-
Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene
-
Steger RW, Chandrashekar V, Zhao W, Bartke A, Horseman ND. Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene. Endocrinology 1998;139:3691-3695.
-
(1998)
Endocrinology
, vol.139
, pp. 3691-3695
-
-
Steger, R.W.1
Chandrashekar, V.2
Zhao, W.3
Bartke, A.4
Horseman, N.D.5
-
11
-
-
0038649182
-
Prostate development and carcinogenesis in prolactin receptor knockout mice
-
Robertson FG, Harris J, Naylor MJ, Oakes SR, Kindblom J, Dillner K, Wennbo H, Tornell J, Kelly PA, Green J, Ormandy CJ. Prostate development and carcinogenesis in prolactin receptor knockout mice. Endocrinology 2003;144:3196-3205.
-
(2003)
Endocrinology
, vol.144
, pp. 3196-3205
-
-
Robertson, F.G.1
Harris, J.2
Naylor, M.J.3
Oakes, S.R.4
Kindblom, J.5
Dillner, K.6
Wennbo, H.7
Tornell, J.8
Kelly, P.A.9
Green, J.10
Ormandy, C.J.11
-
12
-
-
0002525191
-
Structure-function relationships in prolactin
-
Horseman ND, editor, Massachusetts: Kluwer Academic Publishers
-
Lorenson MY, Walker AM. Structure-function relationships in prolactin. In: Horseman ND, editor. Prolactin. Massachusetts: Kluwer Academic Publishers 2001. pp 181-283.
-
(2001)
Prolactin
, pp. 181-283
-
-
Lorenson, M.Y.1
Walker, A.M.2
-
13
-
-
0027368056
-
Dephosphorylation of standard prolactin produces a more biologically active molecule. Evidence for antagonism between non-phosphorylated and phosphorylated prolactin in the stimulation of Nb2 cell proliferation
-
Wang Y-F, Walker AM. Dephosphorylation of standard prolactin produces a more biologically active molecule. Evidence for antagonism between non-phosphorylated and phosphorylated prolactin in the stimulation of Nb2 cell proliferation. Endocrinology 1993;133:2156-2160.
-
(1993)
Endocrinology
, vol.133
, pp. 2156-2160
-
-
Wang, Y.-F.1
Walker, A.M.2
-
14
-
-
0026714560
-
Prolactin isoform 2 as an autocrine growth factor for GH3 cells
-
Krown KA, Wang YF, Ho TW, Kelly PA, Walker AM. Prolactin isoform 2 as an autocrine growth factor for GH3 cells. Endocrinology 1992;131:595-602.
-
(1992)
Endocrinology
, vol.131
, pp. 595-602
-
-
Krown, K.A.1
Wang, Y.F.2
Ho, T.W.3
Kelly, P.A.4
Walker, A.M.5
-
15
-
-
0038408583
-
Different biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways
-
Wu W, Coss D, Lorenson MY, Kuo CB, Xu X, Walker AM. 2003; Different biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways. Biochemistry 2003;42:7561-7570.
-
(2003)
Biochemistry 2003
, vol.42
, pp. 7561-7570
-
-
Wu, W.1
Coss, D.2
Lorenson, M.Y.3
Kuo, C.B.4
Xu, X.5
Walker, A.M.6
-
16
-
-
0037181513
-
p21-activated protein kinase gamma-PAK in pituitary secretory granules phosphorylates prolactin
-
Tuazon PT, Lorenson MY, Walker AM, Traugh JA. p21-activated protein kinase gamma-PAK in pituitary secretory granules phosphorylates prolactin. FEBS Lett 2002;515:84-88.
-
(2002)
FEBS Lett
, vol.515
, pp. 84-88
-
-
Tuazon, P.T.1
Lorenson, M.Y.2
Walker, A.M.3
Traugh, J.A.4
-
17
-
-
0030028521
-
Identification of the major site of rat prolactin phosphorylation as serine 177
-
Wang Y-F, Liu J-W, Mamidi M, Walker AM. Identification of the major site of rat prolactin phosphorylation as serine 177. J Biol Chem 1996;271:2462-2469.
-
(1996)
J Biol Chem
, vol.271
, pp. 2462-2469
-
-
Wang, Y.-F.1
Liu, J.-W.2
Mamidi, M.3
Walker, A.M.4
-
18
-
-
0031790107
-
Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone
-
Chen TJ, Kuo C-YB, Tsai KF, Liu J-W, Chen D-Y, Walker AM. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology 1998;139:609-616.
-
(1998)
Endocrinology
, vol.139
, pp. 609-616
-
-
Chen, T.J.1
Kuo, C.-Y.B.2
Tsai, K.F.3
Liu, J.-W.4
Chen, D.-Y.5
Walker, A.M.6
-
19
-
-
23844481360
-
S179D prolactin increases vitamin D receptor and p21 through upregulation of short lb prolactin receptor in human prostate cancer cells
-
Wu W, Ginsburg E, Vonderhaar BK, Walker AM. S179D prolactin increases vitamin D receptor and p21 through upregulation of short lb prolactin receptor in human prostate cancer cells. Cancer Res 2005;65:7509-7515.
-
(2005)
Cancer Res
, vol.65
, pp. 7509-7515
-
-
Wu, W.1
Ginsburg, E.2
Vonderhaar, B.K.3
Walker, A.M.4
-
20
-
-
33748747780
-
S179D prolactin (PRL) primarily uses the extrinsic pathway and MAPkinase signaling to induce apoptosis in human endothelial cells
-
Ueda E, Lo H-L, Bartolini P, Walker AM. S179D prolactin (PRL) primarily uses the extrinsic pathway and MAPkinase signaling to induce apoptosis in human endothelial cells. Endocrinology 2006;147:4627-4637.
-
(2006)
Endocrinology
, vol.147
, pp. 4627-4637
-
-
Ueda, E.L.H.-L.1
Bartolini, P.2
Walker, A.M.3
-
21
-
-
33745699690
-
Different forms of prolactin have opposing effects on the expression of cell cycle regulatory proteins in differentiated mammary epithelial cells
-
Wu W, Chen YH, Ueda E, Tan D, Bartolini P, Walker AM. Different forms of prolactin have opposing effects on the expression of cell cycle regulatory proteins in differentiated mammary epithelial cells. Oncol Res 2006;16:75-84.
-
(2006)
Oncol Res
, vol.16
, pp. 75-84
-
-
Wu, W.1
Chen, Y.H.2
Ueda, E.3
Tan, D.4
Bartolini, P.5
Walker, A.M.6
-
22
-
-
0036345465
-
Sensitivity to growth suppression by 1 alpha, 25-dihydroxyvitamin D(3) among MCF7 clones correlates with vitamin D receptor protein induction
-
Jensen SS, Madsen MW, Lukas J, Bartek J, Binderup L. Sensitivity to growth suppression by 1 alpha, 25-dihydroxyvitamin D(3) among MCF7 clones correlates with vitamin D receptor protein induction. J Steroid Biochem Mol Biol 2002;81:123-133.
-
(2002)
J Steroid Biochem Mol Biol
, vol.81
, pp. 123-133
-
-
Jensen, S.S.1
Madsen, M.W.2
Lukas, J.3
Bartek, J.4
Binderup, L.5
-
23
-
-
0034889853
-
1,25-DihydroxyvitaminD3 and retinoic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects
-
Wang Q, Lee D, Sysounthone V, Chandraratna RAS, Christakos S, Korah R, Wieder R. 1,25-DihydroxyvitaminD3 and retinoic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res Treat 2001;67:157-168.
-
(2001)
Breast Cancer Res Treat
, vol.67
, pp. 157-168
-
-
Wang, Q.1
Lee, D.2
Sysounthone, V.3
Chandraratna, R.A.S.4
Christakos, S.5
Korah, R.6
Wieder, R.7
-
24
-
-
0036219751
-
Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer
-
Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002;9:45-59.
-
(2002)
Endocr Relat Cancer
, vol.9
, pp. 45-59
-
-
Colston, K.W.1
Hansen, C.M.2
-
25
-
-
33746604877
-
Vitamin D compounds: Clinical development as cancer therapy and prevention agents
-
Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS. Vitamin D compounds: Clinical development as cancer therapy and prevention agents. Anticancer Res 2006;26:2551-2556.
-
(2006)
Anticancer Res
, vol.26
, pp. 2551-2556
-
-
Trump, D.L.1
Muindi, J.2
Fakih, M.3
Yu, W.D.4
Johnson, C.S.5
-
26
-
-
85047680777
-
Antiproliferative effect of 1,25 dihyoxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin D dependent kinase 2 activity and persistent G1 accumulation
-
Zhuang SH, Burnstein KL. Antiproliferative effect of 1,25 dihyoxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin D dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998;139:1197-1207.
-
(1998)
Endocrinology
, vol.139
, pp. 1197-1207
-
-
Zhuang, S.H.1
Burnstein, K.L.2
-
27
-
-
0026601581
-
The human prostatic carcinoma cell line LNCaP express biologically active, specific receptors for 1 alpha, 25-dihyoxyvitamin D3
-
Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. The human prostatic carcinoma cell line LNCaP express biologically active, specific receptors for 1 alpha, 25-dihyoxyvitamin D3. Cancer Res 1992;52:515-520.
-
(1992)
Cancer Res
, vol.52
, pp. 515-520
-
-
Miller, G.J.1
Stapleton, G.E.2
Ferrara, J.A.3
Lucia, M.S.4
Pfister, S.5
Hedlund, T.E.6
Upadhya, P.7
-
28
-
-
33646339673
-
Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer
-
Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 2006;106:2136-2142.
-
(2006)
Cancer
, vol.106
, pp. 2136-2142
-
-
Trump, D.L.1
Potter, D.M.2
Muindi, J.3
Brufsky, A.4
Johnson, C.S.5
-
29
-
-
0037233724
-
Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo
-
Vegesna V, O'Kelly J, Said J, Uskokovic M, Binderup L, Koeffler HP. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res 2003;23:283-289.
-
(2003)
Anticancer Res
, vol.23
, pp. 283-289
-
-
Vegesna, V.1
O'Kelly, J.2
Said, J.3
Uskokovic, M.4
Binderup, L.5
Koeffler, H.P.6
-
30
-
-
0027210024
-
1,25(OH)2-vitaminD3 mediated changes in mRNA for c-myc and 1,25(OH)2D3 receptor in HL-60 cells and related subclones
-
Taoka T, Collins ED, Irino S, Norman AW. 1,25(OH)2-vitaminD3 mediated changes in mRNA for c-myc and 1,25(OH)2D3 receptor in HL-60 cells and related subclones. Mol Cell Endocrinol 1993;95:51-57.
-
(1993)
Mol Cell Endocrinol
, vol.95
, pp. 51-57
-
-
Taoka, T.1
Collins, E.D.2
Irino, S.3
Norman, A.W.4
-
31
-
-
0035477461
-
Growth inhibitory effect of 1,25 dihydroxyvitamin D3 are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-32
-
Moffatt KA, Johannes WU, Hedlund TE, Miller GJ. Growth inhibitory effect of 1,25 dihydroxyvitamin D3 are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-32. Cancer Res 2001;61:7122-7129.
-
(2001)
Cancer Res
, vol.61
, pp. 7122-7129
-
-
Moffatt, K.A.1
Johannes, W.U.2
Hedlund, T.E.3
Miller, G.J.4
-
34
-
-
0031023616
-
Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines
-
Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997;126:83-90.
-
(1997)
Mol Cell Endocrinol
, vol.126
, pp. 83-90
-
-
Zhuang, S.H.1
Schwartz, G.G.2
Cameron, D.3
Burnstein, K.L.4
-
35
-
-
0030611087
-
Stimulation by 1alpha,25(OH)2-vitaminD3 of whole cell chloride currents in osteoblastic ROS 17/2.8 cells. A structure-function study
-
Zanello LP, Norman AW. Stimulation by 1alpha,25(OH)2-vitaminD3 of whole cell chloride currents in osteoblastic ROS 17/2.8 cells. A structure-function study. J Biol Chem 1997;272:22617-22622.
-
(1997)
J Biol Chem
, vol.272
, pp. 22617-22622
-
-
Zanello, L.P.1
Norman, A.W.2
-
36
-
-
1242274642
-
Rapid modulation of osteoblast ion channel responses by 1alpha,25(OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor
-
Zanello LP, Norman AW. Rapid modulation of osteoblast ion channel responses by 1alpha,25(OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor. Proc Natl Acad Sci 2004;101:1589-1594.
-
(2004)
Proc Natl Acad Sci
, vol.101
, pp. 1589-1594
-
-
Zanello, L.P.1
Norman, A.W.2
-
37
-
-
33750922511
-
Non-genomic mechanisms of vitaminD-regulated bone formation in osteoblasts
-
Zanello LP. Non-genomic mechanisms of vitaminD-regulated bone formation in osteoblasts. Clin Cases Miner Bone Metab 2006;3:50-57.
-
(2006)
Clin Cases Miner Bone Metab
, vol.3
, pp. 50-57
-
-
Zanello, L.P.1
-
38
-
-
0032946604
-
1,25-(OH)2D3 modulates growth plate chondrocytes via membrane receptor-mediated protein kinase C by a mechanism that involves changes in phospholipid metabolism and the action of arachidonic acid and P GE2
-
Boyan BD, Sylvia VL, Dean DD, Pedrozo H, Del Toro F, Nemere I, Posner GH, Schwartz Z. 1,25-(OH)2D3 modulates growth plate chondrocytes via membrane receptor-mediated protein kinase C by a mechanism that involves changes in phospholipid metabolism and the action of arachidonic acid and P GE2. Steroids 1999;64:129-136.
-
(1999)
Steroids
, vol.64
, pp. 129-136
-
-
Boyan, B.D.1
Sylvia, V.L.2
Dean, D.D.3
Pedrozo, H.4
Del Toro, F.5
Nemere, I.6
Posner, G.H.7
Schwartz, Z.8
-
39
-
-
17144428054
-
Nongenotropic, antiapoptotic signaling of 1alpha,25(OH)2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes. Mediation by Src, phosphotidylinositol 3-, and JNK kinases
-
Vertino AM, Bula CM, Chen JR, Almeida M, Han L, Bellido T, Kousteni S, Norman AW, Manologas SC. Nongenotropic, antiapoptotic signaling of 1alpha,25(OH)2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes. Mediation by Src, phosphotidylinositol 3-, and JNK kinases. J Biol Chem 2005;280:14130-14137.
-
(2005)
J Biol Chem
, vol.280
, pp. 14130-14137
-
-
Vertino, A.M.1
Bula, C.M.2
Chen, J.R.3
Almeida, M.4
Han, L.5
Bellido, T.6
Kousteni, S.7
Norman, A.W.8
Manologas, S.C.9
-
40
-
-
0023665124
-
Effects of vitamin D3 metabolites on cytosolic free calcium in confluent mouse osteoblasts
-
Lieberherr M. Effects of vitamin D3 metabolites on cytosolic free calcium in confluent mouse osteoblasts. J Biol Chem 1987;262:13168-13173.
-
(1987)
J Biol Chem
, vol.262
, pp. 13168-13173
-
-
Lieberherr, M.1
-
41
-
-
0030769613
-
Assay of direct effect of 1,25-dihydroxyvitaminD3 on calcium ion flux into cultured osteoblasts
-
Meszaros JG, Farach-Carson MC. Assay of direct effect of 1,25-dihydroxyvitaminD3 on calcium ion flux into cultured osteoblasts. Methods Enzymol 1997;282:236-243.
-
(1997)
Methods Enzymol
, vol.282
, pp. 236-243
-
-
Meszaros, J.G.1
Farach-Carson, M.C.2
-
42
-
-
0029737695
-
Transcriptional activation and dimerization functions in the human vitamin D receptor
-
Jin CH, Kerner SA, Hong MH, Pike JW. Transcriptional activation and dimerization functions in the human vitamin D receptor. Mol Endocrinol 1996;10:945-957.
-
(1996)
Mol Endocrinol
, vol.10
, pp. 945-957
-
-
Jin, C.H.1
Kerner, S.A.2
Hong, M.H.3
Pike, J.W.4
-
43
-
-
0027404624
-
Vitamin D, calcium, and epidermal differentiation
-
Bikle DD, Pillai S. Vitamin D, calcium, and epidermal differentiation. Endocrine Rev 1993;14:3-19.
-
(1993)
Endocrine Rev
, vol.14
, pp. 3-19
-
-
Bikle, D.D.1
Pillai, S.2
-
44
-
-
0024510484
-
The role of the vitamin D endocrine system in health and disease
-
Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. New Eng J Med 1989;320:980-991.
-
(1989)
New Eng J Med
, vol.320
, pp. 980-991
-
-
Reichel, H.1
Koeffler, H.P.2
Norman, A.W.3
-
45
-
-
33746641812
-
Calcitriol in the treatment of prostate cancer
-
Beer TM, Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res 2006;26:2647-2651.
-
(2006)
Anticancer Res
, vol.26
, pp. 2647-2651
-
-
Beer, T.M.1
Myrthue, A.2
-
46
-
-
0034210029
-
Synergistic anticancer activity of 1,25 hydoxyvitamin D3 and immune cytokines: The involvement of reactive oxygen species
-
Koren R, Rocker D, Kotestiano O, Liberman UA, Ravid A. Synergistic anticancer activity of 1,25 hydoxyvitamin D3 and immune cytokines: The involvement of reactive oxygen species. J Steroid Biochem Mol Biol 2000;73:105-112.
-
(2000)
J Steroid Biochem Mol Biol
, vol.73
, pp. 105-112
-
-
Koren, R.1
Rocker, D.2
Kotestiano, O.3
Liberman, U.A.4
Ravid, A.5
-
47
-
-
3042687362
-
Targeting 1,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitor
-
Banwell CM, O'Neill PL, Uskokovic MR, Campbell MJ. Targeting 1,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitor. J Steroid Biochem Mol Biol 2004; 89-90. 245-249.
-
(2004)
J Steroid Biochem Mol Biol
-
-
Banwell, C.M.1
O'Neill, P.L.2
Uskokovic, M.R.3
Campbell, M.J.4
-
48
-
-
0035810045
-
Synergistic growth inhibition of prostate cancer cells by 1,25 dihydorxyvitamin D 3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A
-
Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards C, Brown G, Uskokovic MR, Campbell MJ. Synergistic growth inhibition of prostate cancer cells by 1,25 dihydorxyvitamin D 3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 2000;20:1860-1872.
-
(2000)
Oncogene
, vol.20
, pp. 1860-1872
-
-
Rashid, S.F.1
Moore, J.S.2
Walker, E.3
Driver, P.M.4
Engel, J.5
Edwards, C.6
Brown, G.7
Uskokovic, M.R.8
Campbell, M.J.9
-
49
-
-
0036792216
-
Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth
-
Rao A, Woodruff RD, Wade WN, Kute TE, Gramer SD. Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J Nutr 2002;132:3191-3192.
-
(2002)
J Nutr
, vol.132
, pp. 3191-3192
-
-
Rao, A.1
Woodruff, R.D.2
Wade, W.N.3
Kute, T.E.4
Gramer, S.D.5
|